Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks .

What is Agios Pharmaceuticals' stock price target for 2024?

4 equities research analysts have issued 1 year target prices for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $42.00. On average, they expect the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts .

How have AGIO shares performed in 2024?

Agios Pharmaceuticals' stock was trading at $22.27 at the start of the year. Since then, AGIO stock has increased by 32.6% and is now trading at $29.54. View the best growth stocks for 2024 here .

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AGIO earnings forecast .

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.08. The biopharmaceutical company had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative trailing twelve-month return on equity of 38.08%. The firm's quarterly revenue was up 65.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share.

What ETFs hold Agios Pharmaceuticals' stock?

ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT) , Virtus LifeSci Biotech Products ETF (BBP) and WisdomTree BioRevolution Fund (WDNA) . ALPS Medical Breakthroughs ETF (SBIO) .

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com . Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD) , Micron Technology (MU) , Alibaba Group (BABA) , bluebird bio (BLUE) , Pfizer (PFE) , Vertex Pharmaceuticals (VRTX) , NVIDIA (NVDA) , Tesla (TSLA) and Netflix (NFLX) .

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

→ Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad)

Free AGIO Stock Alerts

$29.54

+0.51 (+1.76%)

(As of 01:36 PM ET)

Compare

Today's Range: $29.03
▼
$29.90
50-Day Range: $24.18
▼
$34.81
52-Week Range: $19.80
▼
$35.50

Volume: 229,861 shs
Average Volume: 801,690 shs
Market Capitalization: $1.66 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.50

Get Agios Pharmaceuticals alerts:

Agios Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 13.4% Upside
$33.50 Price Target
Short Interest: Bearish
12.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 1.87
Based on 2 Articles This Week
Insider Trading: Selling Shares
$950,297 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($5.28) to ($5.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

530th out of 914 stocks

Pharmaceutical Preparations Industry

237th out of 416 stocks

2.3

Analyst's Opinion

Consensus Rating
Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Agios Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.06% of the float of Agios Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
Change versus previous month
Short interest in Agios Pharmaceuticals has recently decreased by 3.65%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Agios Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Agios Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Agios Pharmaceuticals is -0.81.

2.7

News and Social Media Coverage

News Sentiment
Agios Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $950,297.00 in company stock.
Percentage Held by Insiders
Only 4.24% of the stock of Agios Pharmaceuticals is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($5.28) to ($5.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agios Pharmaceuticals is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agios Pharmaceuticals is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Agios Pharmaceuticals has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGIO Stock News Headlines

April 12, 2024 | insidertrades.com

Jacqualyn A. Fouse Sells 7,791 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

April 18, 2024 | globenewswire.com

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 10, 2024 | finance.yahoo.com

Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)

April 10, 2024 | americanbankingnews.com

Agios Pharmaceuticals' (AGIO) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

April 9, 2024 | finance.yahoo.com

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

April 2, 2024 | finanznachrichten.de

Oncoinvent AS: Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

March 16, 2024 | finance.yahoo.com

AGIO Apr 2024 40.000 call

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

March 16, 2024 | finance.yahoo.com

AGIO Apr 2024 25.000 put

March 8, 2024 | uk.finance.yahoo.com

Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More

March 5, 2024 | globenewswire.com

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

February 28, 2024 | morningstar.com

Agios Pharmaceuticals Inc AGIO

February 24, 2024 | msn.com

SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry

February 24, 2024 | msn.com

Agios Pharmaceuticals (AGIO) Price Target Increased by 7.00% to 43.66

February 23, 2024 | finance.yahoo.com

Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark

February 22, 2024 | finance.yahoo.com

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

February 22, 2024 | globenewswire.com

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

February 20, 2024 | finance.yahoo.com

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript

February 18, 2024 | finance.yahoo.com

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Reported And Analysts Have Been Cutting Their Estimates

February 17, 2024 | finance.yahoo.com

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Estimates

February 16, 2024 | finance.yahoo.com

Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates

February 16, 2024 | markets.businessinsider.com

Buy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial Prospects

February 16, 2024 | markets.businessinsider.com

Buy Rating Justified by Agios Pharma’s Promising Trials and Future Prospects

February 16, 2024 | finance.yahoo.com

Q4 2023 Agios Pharmaceuticals Inc Earnings Call

February 15, 2024 | finance.yahoo.com

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

February 15, 2024 | finance.yahoo.com

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

See More Headlines

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AGIO
CUSIP: N/A
CIK: 1439222
Web: www.agios.com
Phone: (617) 649-8600
Fax: N/A
Employees: 383
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.50
High Stock Price Target: $42.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +14.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-352,090,000.00
Net Margins: -1,312.64%
Pretax Margin: -1,312.64%
Return on Equity: -38.08%
Return on Assets: -33.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.27
Quick Ratio: 11.99

Sales & Book Value

Annual Sales: $26.82 million
Price / Sales: 61.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.51 per share
Price / Book: 2.02

Miscellaneous

Outstanding Shares: 56,190,000
Free Float: 53,812,000
Market Cap: $1.64 billion
Optionable: Optionable
Beta: 0.83

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Brian M. Goff M.B.A. (Age 55)
CEO & Director
Comp: $1.23M
Ms. Cecilia Jones (Age 49)
Chief Financial Officer
Comp: $403.36k
Mr. James William Burns (Age 46)
Corporate Secretary & Chief Legal Officer
Comp: $660.33k
Dr. Sarah Gheuens M.D. (Age 43)
Ph.D., Chief Medical Officer and Head of Research & Development
Comp: $769.2k
Dr. Lewis Clayton Cantley Ph.D. (Age 75)
Co-Founder & Member of Scientific Advisory Board
Comp: $50k
Dr. Tak Wah Mak D.Sc. (Age 78)
FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. Craig B. Thompson M.D. (Age 71)
Co-Founder & Chairman of Scientific Advisory Board
Dr. Shin-San Su Ph.D. (Age 68)
Co-Founder & Member of Scientific Advisory Board
Mr. T. J. Washburn Jr. (Age 43)
Principal Accounting Officer
Dr. Clive Patience Ph.D. (Age 60)
Chief Technical Operations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price target for 2024?: 4 equities research analysts have issued 1 year target prices for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $42.00. On average, they expect the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2024?: Agios Pharmaceuticals' stock was trading at $22.27 at the start of the year. Since then, AGIO stock has increased by 32.6% and is now trading at $29.54.
View the best growth stocks for 2024 here.
When is Agios Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.08. The biopharmaceutical company had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative trailing twelve-month return on equity of 38.08%. The firm's quarterly revenue was up 65.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share.

What ETFs hold Agios Pharmaceuticals' stock?: ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP) and WisdomTree BioRevolution Fund (WDNA).ALPS Medical Breakthroughs ETF (SBIO).
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?: 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Agios Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
How do I buy shares of Agios Pharmaceuticals?: Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGIO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial